Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

55.53 USD +0.02 (+0.04%)
Official Closing Price Updated: 4:02 PM EDT, Oct 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 332,988
Open 56.00
Bid (Size) 55.00 (1)
Ask (Size) 56.20 (1)
Prev. Close 55.51
Today's Range 54.79 - 56.00
52wk Range 38.95 - 99.36
Shares Outstanding 50,119,272
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Researchers Look for New Ways to Boost Diagnostic Capabilities
FinancialBuzz.com News Commentary 
From PR Newswire
bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystroph
bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel gene therapy for CALD. 
From Business Wire News Releases

Performance

YTD
-35.71%
-35.71%
1 Month
-0.09%
-0.09%
3 Month
-14.91%
-14.91%
6 Month
+3.01%
+3.01%
1 Year
-35.54%
-35.54%

More News

Read More
bluebird bio to Present at Jefferies Cell Therapy Virtual Summit
From Business Wire News Releases
Global Viral Vector Manufacturing Market 2020-2025: Growing Adoption of Adenoviral Vectors, Lentiviral Vectors, as Well as Retroviral Vectors
From PR Newswire
Analysts Expect NIFE Will Reach $63
Tags ETFs
From ETF Channel
bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency
From Business Wire News Releases
Why This Bluebird Bio Analyst Sees Over 125% Upside Ahead
Tags Price Target BLUE Difei Yang
From Benzinga
First Week of December 18th Options Trading For bluebird bio
Tags Stocks
From Market News Video
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
From Business Wire News Releases
bluebird bio Larger Than S&P 500 Component Apache
Tags Stocks
From Market News Video
bluebird bio Announces September Investor Events
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.